3.0
May 11, 2026
Current employee, more than 3 years
Singapur
Recommend
CEO approval
Business Outlook
Pros
Biopharmaceutical plant located in the North of Singapore, very accessible to main island. Salary is fairly decent, much better that other biopharmaceutical companies at Tuas.
Cons
Limited products and facing patent cliff. Competitors for substitute taking up market shares of Factor VIII e.g Hemlibra. Product margin dropping and technology is old. Limited talents, too many mediocre managers, promoted based on long service and loyalty. For a small plant it doesn't create too much of value but waste.